Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry R Davis

Showing results (141-150 of 185) with videos related to

Pageof 19
Sort By:
Lancet (London, England)|November 14, 2021
Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysisMilad Nazarzadeh, Zeinab Bidel, Dexter Canoy, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 29, 2013
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHATWilliam Phillips, Linda B Piller, Jeff D Williamson, et al.
JAMA|April 7, 2005
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinoprilJackson T Wright, J Kay Dunn, Jeffrey A Cutler, et al.
Clinical Trials (London, England)|July 10, 2009
Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination ProjectL Kay Bartholomew, William C Cushman, Jeffrey A Cutler, et al.
Statistics in Medicine|September 11, 2012
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?Michael Proschan, Charles E Ford, Jeffrey A Cutler, et al.
Hypertension (Dallas, Tex. : 1979)|March 21, 2012
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trialMichael H Alderman, Linda B Piller, Charles E Ford, et al.
Archives of Internal Medicine|April 27, 2005
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Mahboob Rahman, Sara Pressel, Barry R Davis, et al.
JACC. Cardiooncology|May 14, 2025
Blood Pressure Lowering and Risk of Cancer: Individual Participant-Level Data Meta-Analysis and Mendelian Randomization StudiesMilad Nazarzadeh, Emma Copland, Karl Smith Byrne, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare DiseasesAdam Wanner, Stephen C Groft, J Russell Teagarden, et al.
Archives of Internal Medicine|May 13, 2009
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analysesJackson T Wright, Jeffrey L Probstfield, William C Cushman, et al.
Pageof 19

Showing results (141-150 of 185) with videos related to

Sort By:
Pageof 19
Lancet (London, England)|November 14, 2021
Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysisMilad Nazarzadeh, Zeinab Bidel, Dexter Canoy, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 29, 2013
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHATWilliam Phillips, Linda B Piller, Jeff D Williamson, et al.
JAMA|April 7, 2005
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinoprilJackson T Wright, J Kay Dunn, Jeffrey A Cutler, et al.
Clinical Trials (London, England)|July 10, 2009
Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination ProjectL Kay Bartholomew, William C Cushman, Jeffrey A Cutler, et al.
Statistics in Medicine|September 11, 2012
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?Michael Proschan, Charles E Ford, Jeffrey A Cutler, et al.
Hypertension (Dallas, Tex. : 1979)|March 21, 2012
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trialMichael H Alderman, Linda B Piller, Charles E Ford, et al.
Archives of Internal Medicine|April 27, 2005
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Mahboob Rahman, Sara Pressel, Barry R Davis, et al.
JACC. Cardiooncology|May 14, 2025
Blood Pressure Lowering and Risk of Cancer: Individual Participant-Level Data Meta-Analysis and Mendelian Randomization StudiesMilad Nazarzadeh, Emma Copland, Karl Smith Byrne, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare DiseasesAdam Wanner, Stephen C Groft, J Russell Teagarden, et al.
Archives of Internal Medicine|May 13, 2009
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analysesJackson T Wright, Jeffrey L Probstfield, William C Cushman, et al.
Pageof 19